CSIMarket
 
Schrodinger Inc   (SDGR)
Other Ticker:  
 
 
Price: $26.0400 $0.29 1.126%
Day's High: $26.12 Week Perf: -1.88 %
Day's Low: $ 25.16 30 Day Perf: -6.16 %
Volume (M): 1,257 52 Wk High: $ 59.24
Volume (M$): $ 32,722 52 Wk Avg: $32.74
Open: $25.52 52 Wk Low: $20.76



 Market Capitalization (Millions $) 1,964
 Shares Outstanding (Millions) 75
 Employees -
 Revenues (TTM) (Millions $) 216
 Net Income (TTM) (Millions $) 41
 Cash Flow (TTM) (Millions $) 65
 Capital Exp. (TTM) (Millions $) 13

Schrodinger Inc
Schrodinger Inc is a leading computational chemistry and biophysics software company that was founded in 1990 by William Goddard III, Michael Levitt, and Peter Kollman. Schrodinger Inc is named after physicist Erwin Schrodinger, who was awarded the Nobel Prize in Physics in 1933 for his contribution to the development of quantum mechanics.

Schrodinger Inc is headquartered in New York City and has additional offices in Europe and Asia. The company is known for its state-of-the-art computational chemistry and biophysics software tools that enable scientists to accurately simulate and predict the behavior of molecules and other biological systems. These tools are used extensively in drug discovery, materials science, and development of biotechnology products.

The company's software platform, Schrodinger Suite, includes a range of software packages that help scientists perform a variety of tasks such as molecular dynamics simulations, ligand-based and structure-based drug design, and protein structure prediction. The software platform is also used to predict and understand the interactions of molecules with biological targets, allowing for more efficient drug discovery.

Schrodinger Inc has a diverse customer base, including academic and government research institutions, biotechnology and pharmaceutical companies, and chemical and materials manufacturers. The company's software tools have been used in several drug discovery projects that have led to the development of successful drugs, including the HIV protease inhibitor Saquinavir and the antipsychotic drug Aripiprazole.

Schrodinger Inc is also actively involved in scientific research and development. The company has a team of scientists who work on developing new software tools and applications, as well as collaborating with academic and industrial partners on various research projects.

Overall, Schrodinger Inc is a leading software company that has made significant contributions to the fields of computational chemistry and biophysics. The company's innovative software tools have played an important role in advancing drug discovery, materials science, and biotechnology, and will continue to be a major force in the scientific community for years to come.


   Company Address: 1540 Broadway New York 10036 NY
   Company Phone Number: 295-5800   Stock Exchange / Ticker: NASDAQ SDGR
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Schrodinger Inc

Major Pharmaceutical Preparations company reports deficit of $-0.38 per share in Q4 2023

Schrodinger Inc's recent financial performance paints a concerning picture for investors. Despite a substantial increase in revenue, the company still posted a loss in the fourth quarter of 2023. This raises red flags about the company's ability to effectively manage its expenses and generate profits.
The fact that Schrodinger Inc's net deficit for the fourth quarter of 2023 was larger than the previous year is particularly troubling. This suggests that the company's financial situation may be worsening, rather than improving. Additionally, the significant increase in accounts receivable could indicate that the company is struggling to collect payments from its customers, which could impact its cash flow and overall financial health.

Schrodinger Inc

Schrodinger Inc Boosts Revenue by 12.599% in Q3 2023, But Reports Losses

Schrodinger Inc Reports Increase in Revenue but Faces Losses in the Third Quarter
Schrodinger Inc, a major pharmaceutical preparations company, recently announced its financial results for the three-month period ending September 30, 2023. While the company witnessed a 12.599% increase in revenue compared to the corresponding quarter a year before, reaching $41.64 million, it also reported a loss per share of $-0.86. This indicates a decline in profitability for the company.
In comparison to the previous quarter, Schrodinger Inc's revenue improved by 18.33% from $35.19 million. However, the company's income per share fell from $0.06 per share, reflecting potential challenges in generating profits. During the July to September 30, 2023 financial period, Schrodinger Inc incurred a net loss of $-62.024 million, a significant increase compared to the net loss of $-39.856 million reported a year ago.

Schrodinger Inc

Schrodinger Inc Posts Positive Earnings of $0.06 per share in Q2 2023, Boosted by $20.43 Million Provisions on Income Taxes; Outperforms Major Pharmaceutical Preparations Sector



The recent release of Schrodinger Inc's second-quarter 2023 financial report has drawn attention from investors and analysts. Despite a decline in revenue, the company managed to turn profitable, posting a positive earnings of $0.06 per share compared to a significant shortfall in the same period the previous year. This article will explore the main highlights of the financial report and shed light on the interesting facts surrounding Schrodinger Inc's performance in the stock market.
Revenue Decline Offset by Positive Earnings:
Despite seeing a drop in revenue by 8.526% from $38.47 million to $35.19 million in Q2 2023 compared to the previous year, Schrodinger Inc achieved a remarkable turnaround in earnings. The company managed to transform a $0.67 per share loss into positive earnings of $0.06 per share. This highlights Schrodinger Inc's ability to optimize its operations and control costs to generate profits even in challenging market conditions.

Schrodinger Inc

Schrodinger Inc's Fiscal First Quarter of 2023 Shows Promising Performance Despite Industry Competition

Investors in Schrodinger Inc should proceed with caution despite the positive news of a record high ROE in the first quarter of 2023. While the company has shown improvement in its net income growth and has turned around to income in the January to March 31, 2023 span, there are several factors to consider before making investment decisions.
Firstly, Schrodinger Inc still lags behind 16 other companies in the Major Pharmaceutical Preparations industry with higher ROEs. This signals that there may be better investment options in the industry that offer higher returns.






 

Schrodinger Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Schrodinger Inc does not provide revenue guidance.

Earnings Outlook
Schrodinger Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com